GlassScriptPhysician profile
Cres P Miranda
NPI 1063420065
$660,323.99
in general payments reported to CMS, 2019-2025
37 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136K · 2020: $28K · 2021: $65K · 2022: $172K · 2023: $79K · 2024: $97K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $222K · Travel and Lodging: $28K · Food and Beverage: $8,542 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $222,241.50 |
| Travel and Lodging | $27,945.14 |
| Food and Beverage | $8,541.66 |
| Education | $138.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $196,998.86 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $108,863.25 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $104,971.79 | 2021-2025 | |
| Esperion Therapeutics, INC. | $57,566.77 | 2020-2024 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $50,788.44 | 2019-2024 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44,849.97 | 2019-2025 | Jardiance |
| Amgen INC. | $30,142.38 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $20,617.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $17,846.11 | 2019-2025 | Verquvo, Steglatro, Winrevair |
| Sanofi-Aventis U.S. LLC | $16,591.08 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $4,518.63 | 2019-2025 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $3,792.92 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $414.83 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Scpharmaceuticals INC. | $258.03 | 2023-2024 | |
| Daiichi Sankyo INC. | $232.66 | 2022-2024 | Injectafer |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $216.12 | 2025 | Attruby |
| Cvrx, INC. | $199.87 | 2021-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $192.77 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $174.39 | 2020-2022 | |
| Akcea Therapeutics, INC. | $144.75 | 2019 | |
| Pfizer INC. | $120.06 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $110.53 | 2022 | |
| Abbott Laboratories | $86.98 | 2022-2023 | Freestyle Libre 2 |
| Amarin Pharma, INC. | $83.91 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $80.53 | 2022-2025 | Amvuttra |
| Corcept Therapeutics | $65.86 | 2022 | |
| Boston Scientific Corporation | $63.29 | 2020-2025 | Watchman Flx |
| Arbor Pharmaceuticals, INC. | $62.98 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.74 | 2019-2023 | Lifevest |
| Cleerly, INC. | $49.55 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals, LTD. | $42.04 | 2021-2023 | Arcalyst |
| Angiodynamics, INC. | $37.54 | 2024 | Angiovac |
| Astellas Pharma US INC | $20.23 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.74 | 2021 | |
| Currax Pharmaceuticals LLC | $17.06 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.23 | 2023 | Inpefa |
| Azurity Pharmaceuticals, INC. | $12.97 | 2023 | Edarbyclor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cres Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.